ArticleThe Journal of infectious diseases2019
Serum Markers Associated with Severity and Outcome of Hantavirus Pulmonary Syndrome.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Prognostic factors for mortality in patients infected with New World hantaviruses: a systematic review and meta-analysis.BMJ open · 2026Pooled it
- Cytokine Profiles and Antibody Response Associated to Choclo Orthohantavirus Infection.Frontiers in immunology · 2021Trial
- Incidence, pathogenesis, clinical manifestations, and pharmacological management of the 2026 Andes virus outbreak.Virology journal · 2026Review
- Bacterial Infection in Ebola Virus Disease, Marburg Virus Disease, Crimean-Congo Hemorrhagic Fever, and Lassa Fever.Open forum infectious diseases · 2026Review
- Omics Approaches in Hantavirus Research: Current Advances, Challenges, and Future Perspectives.Biotech (Basel (Switzerland)) · 2026Review
- The Natural Killer Cell Landscape in the Natural History of Hantavirus Cardiopulmonary Syndrome in a Chilean Cohort.Viruses · 2026Article
- Spectrum of Gastrointestinal, Hepatobiliary, and Pancreatic Involvement in Hantavirus Infection: A Narrative Review.Cureus · 2026Review
- Cross-binding antibodies capable of neutralising diverse hantaviruses are produced in response to Puumala virus infection.EBioMedicine · 2026Article
- Polyfunctional antibody signature defines protection in Andes hantavirus survival.Frontiers in immunology · 2026Article
- Some considerations on hantavirus infections and Andes virus epidemic on the cruise ship Hondius.Le infezioni in medicina · 2026Article
- Pathogenicity and virulence of Rodent-Borne Orthohantaviruses.Virulence · 2025Review
- High genomic stability of Andes virus following successive passageJournal of virology · 2025Article
- IL-6 trans-signaling mediates cytokine secretion and barrier dysfunction in hantavirus-infected cells and correlates to severity in HFRS.PLoS pathogens · 2025Article
- A pan-orthohantavirus human lung xenograft mouse model and its utility for preclinical studies.PLoS pathogens · 2025Article
- Innate lymphoid cells are activated in HFRS, and their function can be modulated by hantavirus-induced type I interferons.PLoS pathogens · 2024Article
- Article
- Infectious and Inflammatory Pathways to Cough.Annual review of physiology · 2023Review
- The kidney in hantavirus infection-epidemiology, virology, pathophysiology, clinical presentation, diagnosis and management.Clinical kidney journal · 2022Review
- BCG-Based Vaccines Elicit Antigen-Specific Adaptive and Trained Immunity against SARS-CoV-2 andVaccines · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHantavirus pulmonary syndrome (HPS) is caused by Andes virus (ANDV) and related hantaviruses in the Americas. Despite a fatality rate of 40%, the pathogenesis of HPS is poorly understood and factors associated with severity, fatality, and survival remain elusive.
methodsNinety-three ANDV-infected HPS patients, of whom 34 had a fatal outcome, were retrospectively studied. Serum levels of cytokines and other inflammation-associated markers were analyzed using multiplex immunoassay and enzyme-linked immunosorbent assay. Associations with disease severity, fatal outcome, and survival were identified using logistic regression.
resultsHPS patients exhibited increased serum levels of markers associated with inflammation, intestinal damage, and microbial translocation compared to controls. Patients with fatal outcome displayed higher levels of interleukin (IL) 6, IL-10, interferon-γ, soluble tumor necrosis factor-related apoptosis-inducing ligand, and intestinal fatty acid-binding protein (I-FABP) than survivors. Levels of complement factor 5/5a were higher in survivors compared with fatal cases. IL-6 and I-FABP, the latter a marker for intestinal damage, were by multivariate analyses identified as independent markers associated with disease severity (odds ratio [OR], 2.25; 95% confidence interval [CI], 1.01-5.01) and fatal outcome (OR, 1.64; 95% CI, 1.01-2.64), respectively.
conclusionsHPS patients displayed a multifaceted, systemic inflammatory response, with IL-6 and I-FABP as independent markers of disease severity and fatality, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.